ѻý
Edit Profile
Manage Subscriptions
CME Tracker
Log Out
Login
Sign Up
ѻý
Back
Allergy & Immunology
Anesthesiology
Cardiology
Critical Care
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics
HIV / AIDS
Hospital-Based Medicine
Infectious Disease
Nephrology
Neurology
Nursing
OB / GYN
Oncology / Hematology
Ophthalmology
Orthopedics
Pain Management
Pathology
Pediatrics
Pharmacy
Primary Care
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Transplantation
Urology
Perspectives
Health Policy
Meetings
Special Reports
Break Room
Conditions
Back
Condition Centers
DocAudio
Making the Rounds
Medical Journeys
Society Partners
Back
AAD Reading Room
ACR Reading Room
AGA Reading Room
ASCO Reading Room
Endocrine Society Reading Room
IDSA Reading Room
OMA Reading Room
Doc Audio
>
Triple-Negative Breast Cancer
I: Why Is YES1 a Good Therapeutic Target in TNBC?
Visit for full episode and transcript.
November 16, 2024 • 5 mins 44 secs
Up Next
I: Why Is YES1 a Good Therapeutic Target in TNBC?
▶ 5 mins
II: Methods for Inhibiting YES1 in TNBC
▶ 4 mins
III: What are the Off-Target Effects of Inhibiting YES1?
▶ 4 mins
IV: Beyond YES1: Future Targets in Breast Cancer
▶ 4 mins
